Thank you for your interest in Gyroscope Therapeutics.
We are committed to advancing treatments for age-related macular degeneration (AMD). We are currently enrolling people with geographic atrophy (GA) secondary to AMD in clinical trials in various locations globally to study the safety and effectiveness of our investigational* gene therapy, which is designed as a one-time treatment that is delivered under the retina.
Currently, our EXPLORE phase II trial is actively recruiting patients: please visit https://clinicaltrials.gov/ct2/show/NCT04437368 to find out more including current clinical trial locations. You may also contact us by phone at 1-888-669-6682 or via email at firstname.lastname@example.org.
*Investigational therapy means that the therapy has not been approved by any regulatory authority and no regulatory authority has determined the therapy to be safe and effective to treat AMD or any other condition.